



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Short communication

# 1*H*-1,2,3-triazole tethered isatin-ferrocene conjugates: Synthesis and *in vitro* antimalarial evaluation



Kewal Kumar<sup>a</sup>, Bruno Pradines<sup>b, c, d</sup>, Marilyn Madamet<sup>c, d, e</sup>, Rémy Amalvict<sup>c, d, e</sup>,  
Nicolas Benoit<sup>c, d, e</sup>, Vipin Kumar<sup>a, \*</sup>

<sup>a</sup> Department of Chemistry, Guru Nanak Dev University, Amritsar 143005, India

<sup>b</sup> Unité de Parasitologie et d'Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France

<sup>c</sup> Aix Marseille Université, Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 63, CNRS 7278, IRD 198, Inserm 1095, Marseille, France

<sup>d</sup> Centre National de Référence du Paludisme, Marseille, France

<sup>e</sup> Equipe Résidente de Recherche en Infectiologie Tropicale, Institut de Recherche Biomédicale des Armées, Hôpital d'Instruction des Armées Laveran, Marseille, France

## ARTICLE INFO

## Article history:

Received 16 September 2014

Received in revised form

6 October 2014

Accepted 9 October 2014

Available online 13 October 2014

## Keywords:

Isatin-ferrocene conjugates

Click chemistry

Structure activity relationship

Antimalarial evaluation

Cytotoxicity

## ABSTRACT

1*H*-1,2,3-triazole tethered isatin-ferrocene conjugates were synthesized and evaluated for their antiplasmodial activities against chloroquine-susceptible (3D7) and chloroquine-resistant (W2) strains of *Plasmodium falciparum*. The conjugates **5f** and **5h** with an optimum combination of electron-withdrawing halogen substituent at C-5 position of isatin ring and a propyl chain, introduced as linker, proved to be most potent and non-cytotoxic among the series with IC<sub>50</sub> values of 3.76 and 4.58 μM against 3D7 and W2 strains, respectively.

© 2014 Elsevier Masson SAS. All rights reserved.

## 1. Introduction

Malaria is one of the most dangerous infectious diseases transmitted through the bite of infected female Anopheles mosquito [1]. Five species of *Plasmodium* viz. *Plasmodium falciparum*, *Plasmodium ovale*, *Plasmodium malariae*, *Plasmodium vivax*, and *Plasmodium knowlesi* are responsible for the spread of malaria, out of which *P. falciparum* is considered as the most virulent form [1]. According to World Health Organization (WHO) factsheet 2013, out of 3.4 billion people at malarial risk, 1.2 billion are at high risk with more than one case per 1000 people, especially in tropical areas with transmission over 97 countries [2]. In 2012, more than 207 million cases were reported globally with an estimated 6,27,000 deaths; 90% of them occurred in sub-Saharan Africa in which 77% were children under the age of five [3]. Since 2006, artemisinin-based combination therapies (ACTs) have been recommended for the treatment of malaria, however, the development of resistance

in the recent times to ACT in many parts of Southeast Asian regions is of great concern [4,5].

Isatin (1*H*-indole-2,3-dione) is a versatile heterocyclic scaffold with vast possibility of chemical modifications at C-3, C-5 and at *N*-1 position [6]. The endogenous molecule displays a wide range of biological and pharmacological activities such as anti-tumor [7–9], anti-HIV [10], antiviral [11], anti-angiogenic [12], antifungal [13,14], anti-Parkinson's disease therapeutic [15], anticonvulsants [16], and effective SARS coronavirus 3CL protease inhibitor [17] along with excellent tolerance in humans. Recently, Chibale and co-workers have disclosed the synthesis and antimalarial activity of a series of thiolactone–isatin conjugates and their tetracyclic by-products [18]. One of the most potent conjugate displayed an IC<sub>50</sub> value of 6.92 μM against chloroquine resistant (CQ-R) W2 strain of *P. falciparum*. Further, Raval et al. described the synthesis of tetrahydropyrimidine–isatin hybrids and their *in vitro* activity against 3D7 strain of *P. falciparum* [19]. The most potent hybrid exhibited minimum inhibitory concentration (MIC) of 0.035 μg/mL which was better than the standard CQ (MIC = 0.125 μg/mL).

Last few years have witnessed a close association between the classical organometallic chemistry to medicine, biology, and

\* Corresponding author.

E-mail address: [vipan\\_org@yahoo.com](mailto:vipan_org@yahoo.com) (V. Kumar).




Fig. 1. Design of target hybrids.

molecular biotechnology [20]. The preparation of stable metal complexes with predictable structures, ability to tune ligand affinities along with efficient biological targeting are the major advantages associated with the synthesis of organometallics [21]. Among all the metals used, ferrocene (Fc) has played a distinctive role in the contemporary medicine because of its unique features including non-toxicity and stability under physiological conditions [22]. The replacement of the organic functionality with Fc has now been recognized as a useful strategy for the development of new and effective drugs *viz.* anti-androgen nilutamide and ferrocenyl analogs of commercial anti-estrogen tamoxifen displayed higher cytotoxicity against breast and prostate cancer cells respectively in comparison to the reference drugs [23]. Indeed, the most symbolic example of contribution of ferrocene with enhanced biological activity into a drug molecule is that of Ferroquine (FQ); derived from chloroquine (CQ) with ferrocene appended side chain which is 22 times more active than CQ against CQ-R strain of *P. falciparum* [24].

1*H*-1,2,3-triazoles are privileged class of five membered nitrogen containing heterocyclic systems which attracted the attention of both synthetic and medicinal chemists due to their synthetic applications and biological potential [25]. The systems are highly stable under the basic, acidic, reductive and oxidative conditions because of high aromatization. Moreover, high dipole moment, rigidity, stability and capability to form hydrogen bonding under *in vivo* conditions are their favorable characteristics in the binding with biological targets.

Previous reports from our group has described the synthesis and *in vitro* antimalarial potential of 1*H*-1,2,3-triazole tethered mono-

and bis-ferrocenylchalcone- $\beta$ -lactam conjugates [26] as well as 7-chloroquinoline-isatin conjugates [27] against chloroquine-susceptible (CQ-S) 3D7 and chloroquine-resistant (CQ-R) W2 strains of *P. falciparum*. In continuation with our interest, the present report describes the synthesis and *in vitro* antimalarial evaluation of 1*H*-1,2,3-triazole tethered isatin-ferrocene conjugates as depicted in Fig. 1.

## 2. Result and discussion


### 2.1. Synthetic chemistry

C-5 substituted *N*-alkylazido-isatins **3** were prepared following our previously reported protocol [28] involving an initial base-promoted alkylation of isatins **1** with dibromoalkanes at 60 °C in DMF to yield the corresponding C-5 substituted *N*-alkylbromo-isatins **2**. The subsequent treatment of **2** with sodium azide at 60 °C resulted in the formation of the desired precursors **3** as depicted in Scheme 1. The precursors' **3** and ethnylferrocene **4** were subsequently utilized in the copper promoted azide-alkyne cycloaddition reaction to yield the desired 1*H*-1,2,3-triazole tethered isatin-ferrocene conjugates **5** [29].

The structure assigned to the hybrids **5** was confirmed on the basis of spectral data and analytical evidences. Compound **5f**, for example, showed a molecular ion peak at  $m/z$  458.0833 [M]<sup>+</sup> while its <sup>1</sup>H NMR spectrum exhibited a singlet at  $\delta$  4.08 corresponding to 5H (cyclopentadiene ring of ferrocene) along with singlets at  $\delta$  4.31 (2H) and  $\delta$  4.72 (2H) due to the ferrocene ring protons. The presence of a characteristic singlet at  $\delta$  7.63 corresponding to the triazole ring proton ascertained the assigned structure which was further corroborated with the number of carbon atoms in the <sup>13</sup>C NMR spectrum.

### 2.2. Antimalarial evaluation

The synthesized conjugates were evaluated for their antimalarial potential against chloroquine-susceptible 3D7 and chloroquine-resistant W2 strains of *P. falciparum* and the corresponding inhibitory concentration 50% (IC<sub>50</sub>s) and 95% confident interval (95%CI) values are enlisted in Table 1. The synthetic precursor *viz.* *N*-alkylbromo-isatins were previously evaluated for their antimalarial potential against chloroquine-resistant W2 strains of *P. falciparum* and have displayed IC<sub>50</sub> values >20  $\mu$ M [18]. As evident from Table 1, the synthesized conjugates were not as active as standard drug chloroquine (CQ) but displayed considerable activity against both the strains. The conjugates **5a–d** with an ethyl chain introduced as linker failed to inhibit the growth of 3D7 even at the highest concentration tested; exception being **5a** (R = H) displaying



Scheme 1. Synthesis of isatin-ferrocene based conjugates.

**Table 1**  
Antiplasmodial activity against the 3D7 and W2 strains of *P. falciparum*.

Compound	R	N	Strains			
			3D7		W2	
			IC <sub>50</sub> (μM)	95% CI	IC <sub>50</sub> (μM)	95% CI
<b>5a</b>	H	2	24.43	20.70–29.90	26.50	21.10–33.40
<b>5b</b>	F	2	>100	–	>100	–
<b>5c</b>	CH <sub>3</sub>	2	>100	–	>100	–
<b>5d</b>	Cl	2	>100	–	>100	–
<b>5e</b>	H	3	6.35	4.78–8.44	7.41	6.13–8.96
<b>5f</b>	F	3	3.76	2.75–7.13	5.97	5.53–6.45
<b>5g</b>	CH <sub>3</sub>	3	16.20	13.70–19.20	9.68	9.05–10.36
<b>5h</b>	Cl	3	8.49	7.83–9.21	4.58	3.86–5.44
<b>CQ</b>			0.021	0.018–0.025	0.49	0.37–0.63

IC<sub>50</sub> values are means of 5 experiments. 95%CI: 95% confident interval.

an IC<sub>50</sub> value of 24.43 μM. Increasing the chain length from ethyl to propyl seemed to have considerable influence on the activity profiles as the conjugates **5e–h** displayed IC<sub>50</sub>s in the range 3.76–16.20 μM. The most potent conjugate **5f** with a fluoro substituent at C-5 position and a propyl linker displayed an IC<sub>50</sub> value of 3.76 μM against 3D7 strain. Similar comparison of structure activity relationship of the synthesized conjugates against W2 strain revealed the ethyl linked conjugates (**5a–d**) to be inactive even at highest tested concentration. The replacement of the ethyl chain with propyl chain again improved the activity profiles with little influence of the nature of substituent introduced at C-5 position of the isatin ring. The conjugate **5n** with electron withdrawing Cl-substituent at C-5 position and *n* = 3 proved to be the most potent with an IC<sub>50</sub> of 4.58 μM.

The improvement in activity profiles of conjugates **5e–h**, over precursors' viz. *N*-alkylbromo-isatins against both CQ-S and CQ-R strains of *P. falciparum* clearly established the importance of amalgamating a ferrocene nucleus among the well established isatin family via triazole-linkers with reputed physicochemical profiles. Although the *in vitro* antimalarial activities of the synthesized isatin-ferrocene conjugates is lower than ferroquine in laboratory strains (2.1–13.4 nM) [30], the conjugates are equipotent as that of ferrocene-ciprofloxacin conjugates [31,32] and ferrocenyl-chalcones such as 1-ferrocenyl-3-(4-nitrophenyl)prop-2-en-1-one [33,34] or mono- and bis-ferrocenylchalcones-β-lactam conjugates [26].

Cytotoxicity of two most potent conjugates viz. **5f** and **5h** was also determined against mammalian HeLa cells and is listed in Table 2. As evident, the conjugates were non-cytotoxic against mammalian cells and therefore had the selectivity for inhibition of *P. falciparum*.

### 3. Conclusion

In conclusion, a series of isatin-ferrocene conjugates have been synthesized via Cu-promoted azide-alkyne cycloaddition reactions and evaluated for their antimalarial activities against the 3D7 and

W2 strains of *P. falciparum*. The improvement in antimalarial efficacy of *N*-alkylbromo-isatins with the introduction of ferrocene nucleus clearly validated the potential of introducing organometallics for improving biological efficacies in present day drug discovery paradigm. The non-cytotoxic conjugates **5f** and **5h** proved to be the most potent among the series with IC<sub>50</sub> values of 3.76 and 4.58 μM against 3D7 and W2 strain of *P. falciparum* respectively.

### 4. Experimental section

Ethynylferrocene was procured from Sigma–Aldrich. Melting points were determined by open capillary using Veego Precision Digital Melting Point apparatus (MP-D) and are uncorrected. <sup>1</sup>H NMR spectra were recorded in deuteriochloroform and dimethylsulfoxide-*d*<sub>6</sub> with Jeol 300 (300 MHz) spectrometers using TMS as an internal standard. Chemical shift values are expressed as parts per million downfield from TMS and *J* values are in hertz. Splitting patterns are indicated as s: singlet, d: doublet, t: triplet, m: multiplet, dd: double doublet, ddd: doublet of a doublet of a doublet, and br: broad peak. <sup>13</sup>C NMR spectra were recorded on Jeol 300 (75 MHz) spectrometers in deuteriochloroform and dimethylsulfoxide-*d*<sub>6</sub> using TMS as internal standard. Elemental analyses were performed on Heraeus CHN–O–Rapid Elemental Analyzer. Mass spectra were recorded on a BRUCKER high resolution mass spectrometer (microTOF-QII). Column chromatography was performed using silica gel (60–120 mesh).

#### 4.1. Procedure for the preparation of isatin ferrocene hybrids (**5a–h**)

Copper sulfate (0.05 mmol) and sodium ascorbate (0.13 mmol) was added to a stirred solution of ethynyl-ferrocene **4** (1 mmol) and *N*-alkylated azido-isatins **3** (1 mmol) in ethanol-water (9:1) mixture. The reaction mixture was allowed to stir at room temperature for 7–10 h. After completion of reaction as evidenced by TLC, water (20 mL) was added and the reaction mixture was extracted twice with dichloromethane (2 × 30 mL). The combined organic layers were dried over anhydrous sodium sulfate, concentrated under reduced pressure and purified via column chromatography using 40:60 (EtOAc: hexane) mixture.

#### 4.2. Methods for assessment of antimalarial activity of test compounds

The two strains viz. 3D7, the CQ-susceptible strain (isolated in West Africa; obtained from MR4, VA, USA), and W2 (isolated in Indochina; obtained from MR4, VA, USA), the CQ-resistant strain, were maintained in culture in RPMI 1640 (Invitrogen, Paisley, United Kingdom), supplemented with 10% human serum (Abcys S.A. Paris, France) and buffered with 25 mM HEPES and 25 mM NaHCO<sub>3</sub>. Parasites were grown in A-positive human blood (Etablissement Français du Sang, Marseille, France) under controlled atmospheric conditions that consisted of 10% O<sub>2</sub>, 5% CO<sub>2</sub> and 85% N<sub>2</sub> at 37 °C with a humidity of 95%.

The two strains were synchronized twice with sorbitol before use [35], and clonality was verified every 15 days through PCR genotyping of the polymorphic genetic markers *msp1* and *msp2* and microsatellite loci [36,37]; additionally, clonality was verified each year by an independent laboratory from the Worldwide Antimalarial Resistance Network (WWARN).

Chloroquine diphosphate (CQ) was purchased from Sigma (Saint Louis, MO). CQ was resuspended in water in concentrations ranging between 5 and 3200 nM. The synthetic compounds were resuspended in DMSO and then diluted in RPMI–DMSO (99v/1v) to obtain final concentrations ranging from 1 nM to 100 μM.

**Table 2**  
Cytotoxicity and selective index of conjugates **5f** and **5h**.

Compound	Strains				
	Cytotoxicity (IC <sub>50</sub> μM)	3D7		W2	
		(IC <sub>50</sub> μM)	SI <sup>a</sup>	(IC <sub>50</sub> μM)	SI <sup>a</sup>
<b>5f</b>	82.14	3.76	21.85	5.97	13.76
<b>5h</b>	86.68	8.49	10.21	4.58	18.93

<sup>a</sup> Selectivity index.



For *in vitro* isotopic microtests, 25  $\mu\text{L}$ /well of antimalarial drug and 200  $\mu\text{L}$ /well of the parasitized red blood cell suspension (final parasitemia, 0.5%; final hematocrit, 1.5%) were distributed into 96 well plates. Parasite growth was assessed by adding 1  $\mu\text{Ci}$  of tritiated hypoxanthine with a specific activity of 14.1 Ci/mmol (Perkin–Elmer, Courtaboeuf, France) to each well at time zero. The plates were then incubated for 48 h in controlled atmospheric conditions. Immediately after incubation, the plates were frozen and thawed to lyse erythrocytes. The contents of each well were collected on standard filter microplates (Unifilter GF/B; Perkin–Elmer) and washed using a cell harvester (Filter-Mate Cell Harvester; Perkin–Elmer). Filter microplates were dried, and 25  $\mu\text{L}$  of scintillation cocktail (Microscint O; Perkin–Elmer) was placed in each well. Radioactivity incorporated by the parasites was measured with a scintillation counter (Top Count; Perkin–Elmer).

The  $\text{IC}_{50}$ , the drug concentration able to inhibit 50% of parasite growth, was assessed by identifying the drug concentration corresponding to 50% of the uptake of tritiated hypoxanthine by the parasite in the drug-free control wells. The  $\text{IC}_{50}$  value was determined by non-linear regression analysis of log-based dose–response curves (Riasmart™, Packard, Meriden, USA).  $\text{IC}_{50}$  are expressed as geometric means of 5 experiments.

#### 4.3. *In vitro* analysis of cytotoxicity on HeLa cells

HeLa cells were cultured in 60  $\times$  15 mm tissue culture dishes containing 5 mL of Dulbecco's Modified Eagle's Medium (DMEM) supplemented with penicillin and streptomycin. Compounds were dissolved in DMSO to 100  $\mu\text{M}$  concentrations. Once cell cultures reached 70% confluency, 5  $\mu\text{L}$  of compound was added to the DMEM in the tissue culture dish for a final concentration of 100  $\mu\text{M}$ . Cells were incubated for 24 h in a 37  $^{\circ}\text{C}$   $\text{CO}_2$  incubator. After 24 h incubation, the media was removed from the HeLa cells and the cells were then washed with 5 mL of 1  $\times$  PBS. The cells were then cleaved off of the bottom of the plate *via* 5-min incubation with 0.5 mL of 0.25% trypsin. Cells were re-suspended in 1 mL of 1  $\times$  PBS and transferred to a micro-centrifuge tube. 100  $\mu\text{L}$  of trypan blue solution was added to the re-suspended cells and allowed to incubate at room temperature for approximately 10 min. Viable and dead cells were visualized and counted with a hemacytometer.  $\text{IC}_{50}$  values were determined using GraphPad PRISM.

#### Acknowledgments

Financial assistance from Department of Science and Technology, New Delhi under Innovation in Science Pursuit for Inspired Research (INSPIRE) Fellowship with code IF-10482 (KK) is gratefully acknowledged.

#### Appendix A. Supplementary data

Supplementary data related to this article can be found at <http://dx.doi.org/10.1016/j.ejmech.2014.10.024>.

#### References

- [1] M. Njoroge, N. M. Njuguna, P. Mutai, D. S. B. Ongarora, P. W. Smith, K. Chibale, (2014) <http://dx.doi.org/10.1021/cr500098f>.
- [2] Factsheet on the World Malaria Report, 2013. [http://www.who.int/malaria/media/world\\_malaria\\_report\\_2013/en/](http://www.who.int/malaria/media/world_malaria_report_2013/en/).
- [3] World Health Organization, World Malaria Report, 2013. Geneva.
- [4] C. Wongsrichanalai, S.R. Meshnick, Emerg. Infect. Dis. 14 (2008) 716.
- [5] A.M. Dondorp, F. Nosten, P. Yi, D. Das, A.P. Phylo, J. Tarning, K.M. Lwin, F. Ariey, W. Hanpithakpong, S.J. Lee, P. Ringwald, K. Silamut, M. Imwong, K. Chotivanich, P. Lim, T. Herdman, S.S. An, S. Yeung, P. Singhasivanon, N.P. Day, N. Lindgardh, D. Socheat, N.J.N. White, Engl. J. Med. 361 (2009) 455.
- [6] G.R. Newkome, W.W. Pandler, Contemporary Heterocyclic Chemistry, Wiley, New York, 1982.
- [7] R. Tripathy, A. Reiboldt, P.A. Messina, M. Iqbal, J. Singh, E.R. Bacon, T.S. Angeles, S.X. Yang, M.S. Albom, C. Robinson, H. Chang, B.A. Ruggeri, J.P. Mallamo, Bioorg. Med. Chem. Lett. 16 (2006) 2158.
- [8] A. Cane, M.C. Tournaire, D. Barritault, M. Crumeyrolle-Arias, Biochem. Biophys. Res. Commun. 276 (2000) 379.
- [9] V.C. Silveira, J.S. Luz, C.C. Oliveira, I. Graziani, M.R. Ciriolo, A.M. Costa-Ferreira, J. Inorg. Biochem. 102 (2008) 1090.
- [10] B.T. Ratan, B. Anand, P. Yogeewari, D. Sriram, Bioorg. Med. Chem. Lett. 15 (2005) 4451.
- [11] T. Jiang, K.L. Kuhen, K. Wolff, H. Yin, K. Bieza, J. Caldwell, B. Bursulaya, T. Tuntland, K. Zhang, D. Karanewsky, Y. He, Bioorg. Med. Chem. Lett. 16 (2006) 2109.
- [12] L. Maskell, E.A. Blanche, M.A. Colucci, J.L. Whatmore, C.J. Moody, Bioorg. Med. Chem. Lett. 17 (2007) 1575.
- [13] R.A. Amal, R. Raghunathan, M.R. Sridevikumaria, N. Raman, Bioorg. Med. Chem. 11 (2003) 407.
- [14] M.C. Rodriguez-Arguelles, S. Mosquera-Vazquez, P. Touron-Touceda, J. Sanmartin-Matalobos, A.M. Garcia-Deibe, M. Belicchi-Ferraris, G. Pelosi, C. Pelizzi, F. Zani, J. Inorg. Biochem. 101 (2007) 138.
- [15] N. Igosheva, C. Lorz, E. O'Conner, V. Glover, H. Mehmet, Neurochem. Int. 47 (2005) 216.
- [16] M. Verma, P.S. Nath, S.K. Nand, J.P. Stables, Acta Pharm. 54 (2004) 49.
- [17] L.R. Chen, Y.C. Wang, Y.W. Lin, S.Y. Chou, S.F. Chen, L.T. Liu, Y.T. Wu, C.J. Kuo, T.S.S. Chen, S.H. Juang, Bioorg. Med. Chem. Lett. 15 (2005) 3058.
- [18] R.H. Hans, I.J.F. Wiid, P.D. van Helden, B. Wan, S.G. Franzblau, J. Gut, P.J. Rosenthal, K. Chibale, Bioorg. Med. Chem. Lett. 21 (2011) 2055.
- [19] T.N. Akhaja, J.P. Raval, Chin. Chem. Lett. 23 (2012) 785.
- [20] G. Gasser, N. Metzler-Nolte, Curr. Opin. Chem. Biol. 16 (2012) 84.
- [21] (a) C. Biot, W. Castro, C.Y. Botte, M. Navarro, Dalton Trans. 41 (2012) 6335; (b) C.G. Hartinger, P.J. Dyson, Chem. Soc. Rev. 38 (2009) 391; (c) G. Jaouen (Ed.), Bioorganometallics: Biomolecules, Labeling, Medicine, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2006.
- [22] D.R. Staveren, N. Metzler-Nolte, Chem. Rev. 104 (2004) 5931.
- [23] (a) S. Top, A. Vessières, G. Leclercq, J. Quivy, J. Tang, J. Vaissermann, M. Huché, G. Jaouen, Chem. Eur. J. 9 (2003) 5223; (b) E. Hillard, A. Vessières, L. Thouin, G. Jaouen, C. Amatore, Angew. Chem. Int. Ed. 45 (2006) 285; (c) O. Payen, S. Top, A. Vessières, E. Brulé, M.A. Plamont, M.J. McGlinchey, H. Müller-Bunz, G. Jaouen, J. Med. Chem. 51 (2008) 1791.
- [24] (a) W. Daher, C. Biot, T. Fandeur, H. Jouin, L. Pelinski, E. Viscogliosi, L. Fraisse, B. Pradines, J. Brocard, J. Khalife, D. Dive, Malar. J. 5 (2006) 11; (b) F. Dubar, J. Khalife, J. Brocard, D. Dive, C. Biot, Molecules 13 (2008) 2900.
- [25] (a) J. Hou, X. Liu, J. Shen, G. Zhao, P.G. Wang, Expert Opin. Drug Discov. 7 (2012) 489. <http://informahealthcare.com/action/doSearch?action=runSearch&type=advanced&result=true&prevSearch=%2Bauthorsfield%3A%28Hou%2C+jingli%29>. <http://informahealthcare.com/action/doSearch?action=runSearch&type=advanced&result=true&prevSearch=%2Bauthorsfield%3A%28Shen%2C+jie%29>; (b) D.M. Beal, L.H. Jones, Angew. Chem. Int. Ed. 51 (2012) 6320; (c) X.P. He, J. Xie, Y. Tang, J. Li, G.R. Chen, Curr. Med. Chem. 19 (2012) 2399; (d) K. Kumar, S. Sagar, L. Esau, M. Kaur, V. Kumar, Eur. J. Med. Chem. 58 (2012) 153.
- [26] K. Kumar, B. Pradines, M. Madamet, R. Amalvict, V. Kumar, Eur. J. Med. Chem. 86 (2014) 113.
- [27] R. Raj, C. Biot, S.C. Kremer, L. Kremer, Y. Guerardel, J. Gut, P.J. Rosenthal, D. Forge, V. Kumar, Chem. Biol. Drug Des. 83 (2014) 622.
- [28] P. Singh, P. Sharma, A. Anand, P.M.S. Bedi, T. Kaur, A.K. Saxena, V. Kumar, Eur. J. Med. Chem. 55 (2012) 455.
- [29] P. Thirumurugan, D. Matosiuk, K. Jozwiak, Chem. Rev. 113 (2013) 4905.
- [30] M. Henry, S. Briolant, A. Fontaine, J. Mosnier, E. Baret, R. Amalvict, T. Fusai, L. Fraisse, C. Rogier, B. Pradines, Antimicrob. Agents Chemother. 52 (2008) 2755.
- [31] F. Dubar, G. Anquetin, B. Pradines, D. Dive, J. Khalife, C. Biot, J. Med. Chem. 52 (2009) 7954.
- [32] F. Dubar, R. Wintjens, E.S. Martins-Duarte, R.C. Vommaro, W. Souza, D. Dive, C. Pierrot, B. Pradines, A. Wohlkonig, J. Khalife, C. Biot, MedChemCom 2 (2011) 430.
- [33] X. Wu, P. Wilairat, M.L. Go, Bioorg. Med. Chem. Lett. 12 (2002) 2299.
- [34] X. Wu, E.R. Tiekink, I. Kostetski, N. Kochorginsky, A.L. Tan, S.B. Khoo, P. Wilairat, M.L. Go, Eur. J. Pharm. Sci. 27 (2006) 175.
- [35] C. Lambros, J.P. Vanderberg, J. Parasitol. 65 (1979) 418.
- [36] H. Bogreau, F. Renaud, H. Bouchiba, P. Durand, S.B. Assi, M.C. Henry, E. Garnotel, B. Pradines, T. Fusai, B. Wade, E. Adehossi, P. Parola, M.O. Kamil, O. Puijalon, C. Rogier, Am. J. Trop. Med. Hyg. 74 (2006) 953.
- [37] M. Henry, I. Diallo, J. Bordes, S. Ka, B. Pradines, B. Diatta, P.S. M'Baye, M. Sane, M. Thiam, P.M. Gueye, B. Wade, J.E. Touze, J.M. Debonne, C. Rogier, T. Fusai, Am. J. Trop. Med. Hyg. 75 (2006) 146.